Benitec Biopharma Inc. (BNTC)

3.1800 -0.0200 (-0.62%) At close: 04:00PM EST

Benitec Biopharma Inc.

3940 Trust Way
Hayward, CA 94545
United States
510 780 0819
https://benitec.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jerel A. Banks M.D., Ph.D.	Executive Chairman & CEO	848.07k	N/A	1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICD	Executive Director	439.17k	N/A	1972
Dr. Michael Graham	Head of Discovery & Founding Scientist	127.29k	N/A	N/A
Dr. Claudia Kloth	Senior Vice President of Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Corporate governance

Benitec Biopharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.